The DOI matches its Crossref record, with a small difference in title or year; 32 of the 32 references it cites were found in a registry or an index.
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Open accessAbstract
BACKGROUND: Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin. METHODS: In this randomized, double-blind, phase 3 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin. All the study patients had completed 6 to 12 months of anticoagulation therapy and were in equipoise regarding the need for continued anticoagulation. Study drugs were administered for up to 12 months. The primary efficacy outcome was symptomatic recurrent fatal or nonfatal venous thromboembolism, and the principal safety outcome was major bleeding. RESULTS: A total of 3365 patients were included in the intention-to-treat analyses (median treatment duration, 351 days). The primary efficacy outcome occurred in 17 of 1107 patients (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%) receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both comparisons). Rates of major bleeding were 0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg of rivaroxaban, and 0.3% in the aspirin group; the rates of clinically relevant nonmajor bleeding were 2.7%, 2.0%, and 1.8%, respectively. The incidence of adverse events was similar in all three groups. CONCLUSIONS: Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates. (Funded by Bayer Pharmaceuticals; EINSTEIN CHOICE ClinicalTrials.gov number, NCT02064439 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Consequently, several studies have investigated the role of aspirin for the secondary prevention of VTE. 309,314,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“and a single study comparing 2 doses of the direct oral anticoagulant rivaroxaban and aspirin found that anticoagulation was more effective than aspirin without an increase in bleeding rates. 314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Self-citationThe Statistical Analysis of Failure Time Data
Klein, J. P. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,215
Research works printed but not linked: 1
- 2012, MMWR Morb Mortal Wkly Rep, 61, 401
Cited by
Items 501–600 of 786
Current Management of Cerebral Venous Thrombosis
Field, T. S., & Fragata, I. (2026) · Stroke · doi:10.1161/strokeaha.125.051340 · Cited by 2
Kroeger, K., Pleye, J., Pourhassan, S., Peter, J., & Noppeney, T. (2018) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-0612-8244 · Cited by 2
Komarov, A. L. (2019) · Kardiologiia · doi:10.18087/cardio.2019.2.10232 · Cited by 2
Treatment of Acute Venous Thromboembolism
Nair, S. N., Garza, N., George, M., & Kaatz, S. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.03.004 · Cited by 3
Camporese, G., Simioni, P., Micco, P. D., Fernández‐Capitán, C., Rivas, A., Font, C., Sahuquillo, J. C., Villares, P., Prandoni, P., Monréal, M., et al. (2020) · Clinical and Translational Science · doi:10.1111/cts.12876 · Cited by 2
Self-citationImpact of direct oral anticoagulants on evolution of post-thrombotic syndrome
Pino, L. D., Francaviglia, B., Frazzetto, M., Valenti, N., & Capranzano, P. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.08.021 · Cited by 2
Khan, F. A., Thavorn, K., Coyle, D., van Katwyk, S., Tritschler, T., Hutton, B., Gal, G. L., Rodger, M. A., & Fergusson, D. A. (2023) · BMJ Open · doi:10.1136/bmjopen-2021-053927 · Cited by 2
Blitz, S. E., Mashouf, L. A., Nieves, A., Matos, J. D., Yaffe, M. B., Davis, R. B., Alterman, R. L., & Stippler, M. (2023) · Neurosurgery · doi:10.1227/neu.0000000000002540 · Cited by 2
Li, J., Ma, S., Jia, X. J., Bu, Y., Zhou, T., Zhang, L., Qiu, M., & Wang, X. (2023) · Trials · doi:10.1186/s13063-023-07461-3 · Cited by 2
Santini, P., Mosoni, C., D’Errico, A., Porceddu, E., Lupascu, A., Valeriani, E., Tondi, P., Pola, R., & Porfidia, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196427 · Cited by 2
Groat, D., Martin, K. A., Rosovsky, R. P. G., Sanfilippo, K. M., Gaddh, M., Kreuziger, L. B., Federici, E. H., & Woller, S. C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010096 · Cited by 2
Rivaroxaban Versus Apixaban: A Comparison Without a Simple Solution
Cohen, M. C., Spyropoulos, A. C., Goodman, S. G., Spinler, S. A., Bonaca, M. P., Redling, T. M., Visveswaran, G. K., & Sohal, S. (2024) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2024.05.004 · Cited by 3
Qiu, Y., Yang, Z., Yang, F.-J., Su, X. Y., Chen, B., & Ni, H.-Z. (2024) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2024.06.019 · Cited by 2
Poli, D. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2441-8902 · Cited by 2
Risk Factors and Management of Cancer-Associated Thrombosis
Vrotniakaite-Bajerciene, K., Carrier, M., & Wang, T. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.01.004 · Cited by 2
Barbosa, L., Oliveira, V. M. R., Araujo, B., Nunes, M. C. P., & Moreira, H. G. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.07.029 · Cited by 2
The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease
Camm, A. J. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1632387 · Cited by 2
Tumorassoziierte venöse Thromboembolie – Pathogenese, Diagnose, Prävention und Therapie
Riess, H. B. (2020) · best practice onkologie · doi:10.1007/s11654-020-00249-w · Cited by 2
Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method
Janknegt, R., Metting, E., Kooistra, J., & Dekhuijzen, R. P. N. (2020) · Acta Scientific Pharmaceutical Sciences · doi:10.31080/asps.2020.04.0640 · Cited by 2
Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis
Isch, J., Nguyen, D. D. T., & Ali, A. N. (2016) · Side effects of drugs annual · doi:10.1016/bs.seda.2016.08.003 · Cited by 2
Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes
Imberti, D., & Mastroiacovo, D. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1688-7 · Cited by 2
Cervi, A. L., & Douketis, J. D. (2018) · Internal and Emergency Medicine · doi:10.1007/s11739-018-1910-2 · Cited by 3
2018 Korean Heart Rhythm Society Guidelines for Non-Vitamin K Antagonist Oral Anticoagulants
Park, Y. M., Park, H. W., Lee, J., Park, J., Lee, K. H., Kim, J., Lee, Y. S., & Joung, B. (2019) · Korean Journal of Medicine · doi:10.3904/kjm.2019.94.1.57 · Cited by 2
Akute Beinvenenthrombose – moderne Diagnostik und Therapie
Thrombose-Initiative e., V., Kröger, K., & Moerchel, C. (2019) · Gefässchirurgie · doi:10.1007/s00772-019-0531-z · Cited by 3
Koroleva, L. Y., Носов, В. П., Zlobina, D. S., & Sadyrin, R. V. (2021) · Journal of Venous Disorders · doi:10.17116/flebo202115031199 · Cited by 2
Antithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_18 · Cited by 4
Bernardi, E., Camporese, G., Bortoluzzi, C., Noventa, F., Ceccato, D., Tonello, C., Vohong, S., Campello, E., Simion, C., Imbalzano, E., et al. (2022) · Life · doi:10.3390/life12111725 · Cited by 2
Sarlon-Bartoli, G., Criado, J., Middeldorp, S., Nieto, J. A., Díaz-Pedroche, M. D. C., Moustafa, F., Ruiz‐Giménez, N., Brenner, B., Monréal, M., Micco, P. D., et al. (2023) · Thrombosis Update · doi:10.1016/j.tru.2023.100148 · Cited by 2
Self-citationAkute Beinvenenthrombose – moderne Diagnostik und Therapie
Thrombose-Initiative e., V., Kröger, K., & Moerchel, C. (2019) · Der Chirurg · doi:10.1007/s00104-018-0771-6 · Cited by 3
Aktuelle Therapie der akuten Lungenembolie
Keller, K., & Lankeit, M. (2019) · Der Pneumologe · doi:10.1007/s10405-019-0266-2 · Cited by 2
Predicción y tratamiento de la hemorragia en pacientes anticoagulados
Páramo, J. A. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2020.06.065 · Cited by 4
Lander, K., Thakeria, P., & Nayyar, S. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab113 · Cited by 2
Comerota, A. J. (2018) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2018.03.011 · Cited by 2
Tapson, V. F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00186-4 · Cited by 2
Kapur, V., & Goyal, S. M. (2023) · Wiley eBooks · doi:10.1002/9781119467779.ch14 · Cited by 2
Cancer-associated Thrombosis in Vietnam: Literature Review and Expert Perspectives
Hoang, S. V., Ho, T. H. Q., Dang, T. H. Q., Nguyen, H. T., Pham, P. C., Do, T. A., Bui, H. H., Nguyen, H. T., Vuong, H. D. T., Dang, D. Q., et al. (2024) · Journal of Applied Hematology · doi:10.4103/joah.joah_102_23 · Cited by 1
Xie, Y., Huang, Y., Stevenson, H. C. S., Li, Y., Zhang, K., Islam, Z. H., Marcum, W. A., Johnston, C., Hoyt, N. E., Kent, E. W., et al. (2024) · Annals of Biomedical Engineering · doi:10.1007/s10439-024-03609-7 · Cited by 3
Anticoagulation for extended venous thromboembolism treatment: less is really more
Middeldorp, S., & Leentjens, J. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00099-6 · Cited by 1
Bardetta, M., Simoncini, M., Valeri, F., Pizzuto, A., Dainese, C., Sella, C., Porreca, A., Bruno, B., & Borchiellini, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14175991 · Cited by 1
Valeriani, E., Pannunzio, A., Brogi, T., Palumbo, I., Menichelli, D., Marucci, S., Tretola, L., Mastroianni, C. M., Pastori, D., & Pignatelli, P. (2025) · Diagnostics · doi:10.3390/diagnostics15172283 · Cited by 1
Zhang, R., Wang, R., Li, Y., Tian, W., Niu, D., Cheng, W., & Niu, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1708316 · Cited by 1
Managing patients with a history of arterial disease and new venous thromboembolism
Deng, E., & Passam, F. H. (2025) · Hematology · doi:10.1182/hematology.2025000683 · Cited by 1
Anticoagulation in malignancy: the patient who bleeds and clots simultaneously
Kapoor, S., Peseski, A. M., & Ortel, T. L. (2025) · Hematology · doi:10.1182/hematology.2025000703 · Cited by 1
Deng, D., Xu, Z., & Zhu, W. (2025) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296251408061 · Cited by 1
de Matos, U. M. A., Itaya, E. D., Meldola, P. F., Danielian, P. L. L. B., Kumar, S., & Vankina, R. (2026) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2026.2662102 · Cited by 1
Optimal duration of anticoagulant therapy in patients with venous thromboembolism
Palareti, G. (2018) · Italian Journal of Medicine · doi:10.4081/item.2018.1077 · Cited by 1
Liang, J., Alavinia, M., & Kumbhare, D. A. (2018) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000001046 · Cited by 1
Hu, J., Chan, K., Adhikari, N., & Khan, A. (2021) · Cureus · doi:10.7759/cureus.18048 · Cited by 1
Kimmerle, A., Noflatscher, M., & Raggam, R. B. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001106 · Cited by 1
Barrera, J. R., Herrero, F. Á., Sánchez, A. B., Cabeza, O. U., Blanco, A. B., & Martín-Conejero, A. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.06.022 · Cited by 1
Chen, J., Liu, S., Shen, Y., Xiong, H., Chen, C., Xiao, B., Wang, Y., Lu, J., Yu, W., Xu, D., et al. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2706-9879 · Cited by 1
LYRA, G. O. T., Katsuyama, E. S., Pincelli, M. P., de Almeida, V. P., Prado, M. L. D. L., Pereira, S. B., Tinoco, J. A., Nunes, M. A. P., & Fernandes, C. J. C. D. S. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.12.012 · Cited by 1
Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism
Nusrat, S., Khan, S., Beg, K. A., & Raskob, G. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041756 · Cited by 1
Ali, M. F., Naseer, F., Hageen, A. W., Hayat, S., Rashid, Z., Momna, F. N. U., Sawaira, F., Riaz, A. A., Ahmad, H. F., Eltawansy, S., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70142 · Cited by 1
Malte, A. L., Abilgaard, A. M., Højbjerg, J. A., Hellfritzsch, M., Grove, E. L., & Larsen, J. B. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109759 · Cited by 1
Highlights from ACC.17 scientific sessions
Yılmaz, M. B. (2017) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2017.7903 · Cited by 1
Polyantsev, A. A., Mozgovoy, P. V., Frolov, D. V., Linchenko, A. M., Shchelokova, Y. V., Litvinova, T. A., Dyakova, Y. A., & Frolenko, I. A. (2018) · Pirogov Russian Journal of Surgery · doi:10.17116/hirurgia2018133-40 · Cited by 1
Anticoagulants and Treatment of Venous Thromboembolism
Burnett, A., & Ansell, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-97873-4_17 · Cited by 1
Direct factor Xa inhibitor in the prevention of thromboembolism
Meretskyi, V., Meretska, I., & Pertsovych, V. M. (2019) · Health Problems of Civilization · doi:10.5114/hpc.2018.79987 · Cited by 1
Antithrombotic dose: Some observations from published clinical trials
Dimmitt, S. B., Floyd, C. N., & Ferner, R. E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13968 · Cited by 1
Moderne Therapie tiefer Venenthrombosen und der Lungenarterienembolie
Renczes, J., & Lindhoff‐Last, E. (2019) · Der Internist · doi:10.1007/s00108-019-0609-4 · Cited by 2
Paoletti, E., REZKALLAH, S., Harake, S. E., Castelli, M., Benresdouane, Y., Brunet, D., Suchon, P., Morange, P., & Sarlon-Bartoli, G. (2020) · JMV-Journal de Médecine Vasculaire · doi:10.1016/j.jdmv.2020.04.012 · Cited by 1
Benz, A. P., & Eikelboom, J. W. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.07.023 · Cited by 1
Decision-Making in the Management of Venous Thromboembolism
Ellis, M. H., & Avnery, O. H. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.09.027 · Cited by 3
Zaharodny, H. M. (2021) · Sports medicine research and practice · doi:10.47529/2223-2524.2021.1.6 · Cited by 1
Sánchez, F. S. L., Hernández, P. V., Castillo, J. Z., & Calvo, R. S. (2021) · Angiología · doi:10.20960/angiologia.00313 · Cited by 1
Pharmacologic Treatment of Pulmonary Embolism
Raccah, B. H., Kalish, Y., Jabara, R., Herzog, E., & Roth, B. (2021) · Springer eBooks · doi:10.1007/978-3-030-87090-4_11 · Cited by 1
Antithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_18 · Cited by 1
Romanova, M. V., & Владимирович, П. Д. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-4944 · Cited by 1
Kanjee, Z., Freed, J. A., Carroll, B., & Reynolds, E. E. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0989 · Cited by 1
Yamazoe, S., Imai, H., Ogawa, Y., Kano, N., Murase, Y., Mamiya, K., Ikeda, T., Hiramatsu, K., Torii, J., & Kawaguchi, K. (2024) · Heart and Vessels · doi:10.1007/s00380-023-02339-5 · Cited by 1
Попонина, Т. М., Poponina, Y. S., & Ryabov, V. V. (2024) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2024-39-1-194-201 · Cited by 1
TROMBOEMBOLISMO PULMONAR: DESAFIOS NO DIAGNÓSTICO, TRATAMENTO E PREVENÇÃO
Trindade, A. C., do Monte, B. B., de Andrade, B. V., Furquim, E. C. G., Filho, H. J. D. C. F., Ribeiro, I. G., de Miranda, M. G., Lima, M. D. A., & Uziel, S. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024479p333 · Cited by 1
Александровна, Ш. Е., Penskaya, T. Y., Gruzdeva, O. V., Berns, S. A., Каретникова, В. Н., & Барбараш, О. Л. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3869 · Cited by 1
Duration of anticoagulation of venous thromboembolism
Couturaud, F., Meneveau, N. F., Sevestre, M., Morange, P., & Jiménez, D. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104245 · Cited by 1
del Pozo, M. M., Asenjo, M. M., Franco‐Moreno, A., de Antonio, E. U., & Valle, F. G. (2024) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2024.10.004 · Cited by 1
Anticoagulation Therapy for Venous Thromboembolism
Anjum, P., Utz, A. E., Kimbrell, M., & Akbashev, M. Y. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.02.017 · Cited by 3
The Aftermath of Pulmonary Embolism: Are Residual Thrombi Clinically Significant?
Pocienė, I., & Danila, E. (2025) · Diagnostics · doi:10.3390/diagnostics15111348 · Cited by 1
Quel traitement anticoagulant au décours d’une embolie pulmonaire
Mao, R. L., Tromeur, C., & Couturaud, F. (2017) · La Presse Médicale · doi:10.1016/j.lpm.2017.06.015 · Cited by 1
Venous thromboembolism in Portuguese hospitals: Where we stand and how we can improve
Castro, G. (2017) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2017.10.005 · Cited by 1
Anticoagulants oraux directs (AOD) : une mise au point nécessaire
Laroche, J.-P., Becker, F., & Schved, J. (2018) · JMV-Journal de Médecine Vasculaire · doi:10.1016/j.jdmv.2018.02.005 · Cited by 1
The year 2017 in cardiology: aorta and peripheral circulation
Aboyans, V., Brækkan, S. K., Mazzolai, L., Sillesen, H. H., Venermo, M. A., & Carlo, M. D. (2018) · Cardiologia Croatica · doi:10.15836/ccar2018.99 · Cited by 1
Abdel‐Razeq, H., Finianos, A. N., & Taher, A. T. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1480363 · Cited by 1
Lawall, H. (2018) · Gefässchirurgie · doi:10.1007/s00772-018-0402-z · Cited by 1
The Management of Venous Thromboembolic Disease
Obi, A. T., & Wakefield, T. W. (2018) · Advances in Surgery · doi:10.1016/j.yasu.2018.03.005 · Cited by 1
Zawilska, K. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0009 · Cited by 1
A MODERN APPROACH TO THE TREATMENT AND PROPHYLAXIS OF VENOUS THROMBOEMBOLISM. PART II
Shalnev, V. I. (2018) · EMERGENCY MEDICAL CARE · doi:10.24884/2072-6716-2017-18-4-60-65 · Cited by 1
Die verlängerte Sekundärprophylaxe nach venöser Thrombose
Bauersachs, R. M., & Schimmelpfennig, J. (2018) · Phlebologie · doi:10.12687/phleb2448-6-2018 · Cited by 1
Self-citationUpdates in venous thromboembolism management: evidence published in 2017
Bartlett, M. A., Bierle, D. M., Saadiq, R. A., Mauck, K. F., & Daniels, P. R. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1486676 · Cited by 1
Thomas, W., Symington, E. M., Besser, M. W., & Sheares, K. K. K. (2019) · British Journal of Haematology · doi:10.1111/bjh.15880 · Cited by 1
Cardioembolic stroke, the basis of diagnosis and prevention
Mukhin, A. S., Medvedev, A. P., Ivanova, Y. A., & Федоров, С. А. (2019) · Medical Almanac · doi:10.21145/2499-9954-2019-2-55-58 · Cited by 1
Aktuelles Management der Lungenembolie
Konstantinides, S., & Hobohm, L. (2020) · CardioVasc · doi:10.1007/s15027-020-0419-6 · Cited by 1
Terapia Anticoagulante para Tratamento da Trombose Venosa Profunda – O Que Há de Novo?
Sanches, S. M. V. (2020) · Revista Científica Hospital Santa Izabel · doi:10.35753/rchsi.v3i1.37 · Cited by 3
Long term use of anticoagulant therapy for patients with pulmonary embolism
Becattini, C., & Cimini, L. A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1770589 · Cited by 1
Oral factor Xa inhibitors and risk of subdural hematoma
Catanese, L., Eikelboom, J. W., Bosch, J., Shestakovska, O., Ng, K., Nayar, S., Perera, K. S., Shoamanesh, A., Sharma, M., & Hart, R. G. (2020) · Neurology · doi:10.1212/wnl.0000000000009826 · Cited by 1
Management of the Acute Thrombus-Bearing IVC Filter
Lessne, M. L., & Holly, B. P. (2020) · Springer eBooks · doi:10.1007/978-3-030-45150-9_13 · Cited by 2
The relevance of acetylsalicylic acid preparations for prevention cardiovascular disease
Gruzin, T. V., & Sorokina, Y. А. (2020) · doi:10.18411/lj-06-2020-33 · Cited by 1
Recent advances in preventing recurrent stroke
Spence, J. D. (2020) · F1000Research · doi:10.12688/f1000research.23199.1 · Cited by 1
Graham, W. B., & Tapson, V. F. (2020) · Respiratory medicine · doi:10.1007/978-3-030-51736-6_11 · Cited by 1
Current concepts of anticoagulant and antiplatelet therapy in patients with vascular pathology
Sapelkin, S. V., & Kuznetsov, M. R. (2020) · Angiology and vascular surgery · doi:10.33529/angi02020305 · Cited by 1
Metadata
- Authors
- Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., Freitas, M. C. S., Holberg, G., Kakkar, A. K., Haskell, L., van Bellen, B., Pap, A. F., Berkowitz, S. D., Verhamme, P., Wells, P. S., & Prandoni, P.
- Affiliations
- University of Ottawa (CA)
- University of Geneva (CH)
- University of Padua (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-30
- Volume
- 376
- Issue
- 13
- Pages
- 1211-1222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2595086780
- Cited by
- 787
- References
- 32
- Citations by year
- 2026: 58 · 2025: 77 · 2024: 65 · 2023: 49 · 2022: 78 · 2021: 97 · 2020: 92 · 2019: 96 · 2018: 123 · 2017: 50
- FWCI
- 104.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Ionis Pharmaceuticals
- Janssen Scientific Affairs
- Novo Nordisk
- Novo Nordisk Fonden (NNF12OC1015957)
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- venous thromboembolism, rivaroxaban, aspirin, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, low-dose rivaroxaban, thromboprophylaxis, direct oral anticoagulants, adverse events, dose comparison, post-thrombotic syndrome
- MeSH terms
- Rivaroxaban, Adult, Aged, Aspirin, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Kaplan-Meier Estimate, Venous Thromboembolism, Secondary Prevention, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.